Guardant: Double-Digit Sales Projections Come At A Cost Guardant Health, Inc. (GH) Q1 2024 Earnings Call Transcript Guardant Health stock jumps as FDA clears blood test for colorectal cancer screening ...

to introduce a non-invasive blood-based screening program for colorectal cancer using Guardant’s Shield™ test. The agreement was set up through Hikma Pharmaceuticals PLC, a multinational ...

(NASDAQ:GH) announced that Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted coverage for the Guardant Reveal test to ...

Guardant Health has secured Medicare coverage from Palmetto for its blood test to monitor for disease recurrence in patients with colorectal cancer. Guardant, a biotechnology company, provides a blood ...

The company’s fourth-quarter numbers also covered the first full quarter following the launch of Guardant’s Shield blood test for colorectal cancer screening, following its approval by the FDA ...

Investing.com -- Shares of Guardant Health (NASDAQ:GH) have increased by 5.0% in premarket trading Tuesday following the company's announcement that its Guardant Reveal test for colon cancer has ...

which runs on Guardant’s Smart Liquid Biopsy platform, is a blood test that uses epigenomic (methylation) analysis to detect circulating tumor DNA (ctDNA), a marker of minimal residual disease ...

Health officials introduce blood test as a more pleasant option to encourage greater participation in screening and boost early detection of colorectal cancer Guardant Health, Inc. (Nasdaq ...

a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted coverage for the Guardant Reveal test to monitor for disease recurrence in patients ...

Guardant Health (GH) and Meaningful Insights Biotech Analytics, or MiBA announced a partnership aimed at optimizing the use of biomarker testing and data analytics to advance precision medicine in ...